Ovarian cancer: Individualized and personalized care

Expert Review of Obstetrics and Gynecology

Volumn 5, Issue 4, 2010, Pages 409-419

  Growdon, Whitfield B ^a   Birrer, Michael J ^a   Penson, Richard T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

biologic; novel; personalized; targeted

Indexed keywords

2 CHLORO N [4 CHLORO 3 (2 PYRIDINYL)PHENYL] 4 METHANESULFONYLBENZAMIDE; 4 IODO 3 NITROBENZAMIDE; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM COMPLEX; SELUMETINIB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB;

CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CYTOREDUCTIVE SURGERY; ENDOMETRIOID CARCINOMA; GENE EXPRESSION PROFILING; HUMAN; MOLECULARLY TARGETED THERAPY; OVARY CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; REVIEW;

EID: 77954514947     PISSN: 17474108     EISSN: None     Source Type: Journal    
DOI: 10.1586/eog.10.35     Document Type: Review

References (105)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 374, 1371-1382 (2009).
3. Vergote I. EORTC-GCG/NCIC-CTG trial 55971 randomized comparing primary debulking surgery (PDS) with neoadjuvant chemotherapy (NACT) followed by interval debulking (IDS) in stage IIIC-IV ovarian, fallopian tube, and peritoneal cancer. Presented at: International Gynecologic Cancer Society. Bangkok, Thailand, 25-28 October 2008.
4. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3194-3200 (2003).
5. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34-43 (2006).
6. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6, 279-286 (2005).
7. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7, 2958-2970 (2001).
8. Heimberger AB, Learn CA, Archer GE et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8, 3496-3502 (2002).
9. Magne N, Fischel JL, Dubreuil A et al. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br. J. Cancer 86, 819-827 (2002).
10. Moulder SL, Yakes FM, Muthuswamy SK et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)- overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61, 8887-8895 (2001).
11. Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br. J. Cancer 90, 2250-2255 (2004).
12. Baselga J. A review of EGFR targeted therapy. Clin. Adv. Hematol. Oncol. 1, 218-219 (2003).
13. Arribas J, Baselga J. Who will benefit from treatment against EGFR? Lancet Oncol. 6, 257-258 (2005).
14. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23, 2445-2459 (2005).
15. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp. Cell Res. 284, 122-130 (2003).
16. Hirsch FR, Varella-Garcia M, Cappuzzo F et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. 18, 752-760 (2007).
17. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
18. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst. 97, 643-655 (2005).
19. Hirsch FR, Varella-Garcia M, McCoy J et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 23, 6838-6845 (2005).
20. Chung CH, Ely K, McGavran L et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 24, 4170-4176 (2006).
21. Jeon YK, Sung SW, Chung JH et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54, 387-398 (2006).
22. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21, 3798-3807 (2003).
23. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174 (2008).
24. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J. Clin. Oncol. 20, 1932-1941 (2002).
25. Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006).
26. Nevins JR, Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat. Rev. Genet. 8, 601-609 (2007).
27. Potti A, Nevins JR. Utilization of genomic signatures to direct use of primary chemotherapy. Curr. Opin. Genet. Dev. 18, 62-67 (2008).
28. Berchuck A, Iversen ES, Lancaster JM et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin. Cancer Res. 11, 3686-3696 (2005).
29. Bonome T, Lee JY, Park DC et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 65, 10602-10612 (2005).
30. Lancaster JM, Dressman HK, Whitaker RS et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J. Soc. Gynecol. Investig. 11, 51-59 (2004).
31. Mok SC, Bonome T, Vathipadiekal V et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16, 521-532 (2009).
32. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 9, 415-428 (2009).
33. Spentzos D, Levine DA, Ramoni MF et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J. Clin. Oncol. 22, 4700-4710 (2004).
34. Zorn KK, Bonome T, Gangi L et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 11, 6422-6430 (2005).
35. Bookman MA, Brady MF, McGuire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27, 1419-1425 (2009).
36. Dressman HK, Berchuck A, Chan G et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 25, 517-525 (2007).
37. Hall J, Paul J, Brown R. Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev. Mol. Med. 6(12), 1-20 (2004).
38. Havrilesky L, Darcy M, Hamdan H et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 21, 3814-3825 (2003).
39. Vasey PA, Shulman LN, Campos S et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20, 1562-1569 (2002).
40. Buller RE, Runnebaum IB, Karlan BY et al. A Phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9, 553-566 (2002).
41. Bookman MA, Darcy KM, Clarke-Pearson D et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21, 283-290 (2003).
42. Mayr D, Kanitz V, Amann G et al. HER-2/ neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology 48, 149-156 (2006).
43. Tuefferd M, Couturier J, Penault-Llorca F et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2, e1138 (2007).
44. Risch HA, McLaughlin JR, Cole DE et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl Cancer Inst. 98, 1694-1706 (2006).
45. Berchuck A, Cirisano F, Lancaster JM et al. Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am. J. Obstet. Gynecol. 175, 738-746 (1996).
46. Narod SA, Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr. Opin. Obstet. Gynecol. 14, 19-26 (2002).
47. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a BRCA1 mutation. Cancer Res. 61, 4842-4850 (2001).
48. Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur. J. Cancer 46, 9-20 (2010).
49. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785-3790 (2008).
50. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
51. Audeh M, Penson R, Friedlander M. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J. Clin. Oncol. 27(Suppl.), 15s (2009) (Abstract 5500).
52. O'Shaughnessy JO. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized Phase II trial. Am. Soc. Clin. Oncol. 27(Suppl.), 18s (2009) (Abstract 3).
53. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429-4434 (2007).
54. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 95, 1482-1485 (2003).
55. Press JZ, De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8, 17 (2008).
56. Santin AD, Hermonat PL, Ravaggi A et al. Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstet. Gynecol. 94, 78-82 (1999).
57. Cooper BC, Ritchie JM, Broghammer CL et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res. 8, 3193-3197 (2002).
58. Yokoyama Y, Charnock-Jones DS, Licence D et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br. J. Cancer 88, 237-244 (2003).
59. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25, 5180-5186 (2007).
60. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25, 5165-5171 (2007).
61. Tuma RS. Success of bevacizumab trials raises questions for future studies. J. Natl Cancer Inst. 97, 950-951 (2005).
62. Lee FYF, Castaneda S, Hawken D. Bevacizumab/ixabepilone (BMS-247550) combination produces synergistic antitumor efficacy in multiple tumor in vivo and is superior to bevacizumab/ paclitaxel combination. Presented at: AACR-EORTC-NCI International Conference. Philadelphia, PA, USA, 14-18 November 2005 (Poster B246).
63. Penson RT, Dizon DS, Cannistra SA et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J. Clin. Oncol. 28, 154-159 (2010).
64. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br. J. Cancer 100, 1-7 (2009).
65. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006).
66. Giantonio BJ. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings. Semin. Oncol 33, S15-S18 (2006).
67. Hirai H, Iwasawa Y, Okada M et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol. Cancer Ther. 8, 2992-3000 (2009).
68. Iorns E, Lord CJ, Grigoriadis A et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS ONE 4, e5120 (2009).
69. Konecny GE, Glas R, Dering J et al. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br. J. Cancer 101, 1699-1708 (2009).
70. Rose SL. Notch signaling pathway in ovarian cancer. Int. J. Gynecol. Cancer 19, 564-566 (2009).
71. Bakkum-Gamez JN, Aletti G, Lewis KA et al. Mullerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol. Oncol. 108, 141-148 (2008).
72. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510 (2008).
73. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
74. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3, 1221-1224 (2004).
75. Abubaker J, Bavi P, Al-Haqawi W et al. PIK3CA alterations in Middle Eastern ovarian cancers. Mol. Cancer 8, 51 (2009).
76. Souglakos J, Philips J, Wang R et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer 101, 465-472 (2009).
77. Kalinsky K, Jacks LM, Heguy A et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin. Cancer Res. 15, 5049-5059 (2009).
78. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 12, 104-107 (2007).
79. Salvesen HB, Carter SL, Mannelqvist M et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc. Natl Acad. Sci. USA 106, 4834-4839 (2009).
80. Shayesteh L, Lu Y, Kuo WL et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21, 99-102 (1999).
81. Campbell IG, Russell SE, Choong DY et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681 (2004).
82. Kolasa IK, Rembiszewska A, Felisiak A et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol. Ther. 8, 21-26 (2009).
83. Kuo KT, Mao TL, Jones S et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol. 174, 1597-1601 (2009).
84. Dent P, Grant S, Fisher PB et al. PI3K: a rational target for ovarian cancer therapy? Cancer Biol. Ther. 8, 27-30 (2009).
85. Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol. Cancer Ther. 8, 1-9 (2009).
86. Serra V, Markman B, Scaltriti M et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68, 8022-8030 (2008).
87. Singer G, Oldt R, 3rd, Cohen Y et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl Cancer Inst. 95, 484-486 (2003).
88. Singer G, Shih Ie M, Truskinovsky A et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int. J. Gynecol. Pathol. 22, 37-41 (2003).
89. Mayr D, Hirschmann A, Lohrs U et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol. Oncol. 103, 883-887 (2006).
90. Kuo KT, Guan B, Feng Y et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 69, 4036-4042 (2009).
91. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 27, 151-160 (2008).
92. Schickedanz A. Of value: a discussion of cost, communication, and evidence to improve cancer care. Oncologist 15(Suppl. 1), 73-79 (2010).
93. Williamson S. Patient access schemes for high-cost cancer medicines. Lancet Oncol. 11, 111-112 (2010).
94. Lipscomb J. Estimating the cost of cancer care in the United States: a work very much in progress. J. Natl Cancer Inst. 100, 607-610 (2008).
95. Meropol NJ, Schrag D, Smith TJ et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J. Clin. Oncol. 27, 3868-3874 (2009).
96. Ramaswamy S. Rational design of cancer-drug combinations. N. Engl. J. Med. 357, 299-300 (2007).
97. Galic V, Willner J, Wollan M et al. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 46, 239-247 (2007).
98. Cannistra SA. Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529 (2004).
99. Markman M, Liu PY, Moon J et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group Phase 3 trial. Gynecol. Oncol. 114, 195-198 (2009).
100. Bruel-Jungerman E, Veyrac A, Dufour F et al. Inhibition of PI3K-Akt signaling blocks exercise-mediated enhancement of adult neurogenesis and synaptic plasticity in the dentate gyrus. PLoS ONE 4, e7901 (2009).
101. Rustin GW. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). American Society of Clinical Oncology Annual Meeting (ed 18s). J. Clin. Oncol. Chicago, IL, USA (2009).
102. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8, 963-968 (1997).
103. Harter P, Hahmann M, Lueck HJ et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann. Surg. Oncol. 16, 1324-1330 (2009).
104. Doyle C, Crump M, Pintilie M et al. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J. Clin. Oncol. 19, 1266-1274 (2001).
105. ClinicalTrials.gov. Sunitinib Malate in Treating Patients with Persistent or Recurrent Clear Cell Ovarian Cancer (NCT00979992) http://clinicaltrials.gov/ ct2/show/ NCT00979992